The UK Insulin Delivery Device Market was valued at $256.3 Million in 2025 and projected to reach to $328.4 Million by 2030, representing a compound annual growth rate of 5.1%. The UK insulin delivery device market is positioned for steady growth through 2030, supported by increasing diabetes prevalence, NHS investment in diabetes management technologies, and patient demand for user-friendly delivery systems.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
The UK insulin delivery device market is valued at $256.3 million in 2025, with projected growth to $328.4 million by 2030, reflecting steady expansion in the region's diabetes management sector.
The UK benefits from the NHS's comprehensive diabetes care programs and established reimbursement pathways, facilitating widespread adoption of advanced insulin delivery technologies across the nation.
Strong uptake of insulin pens, pumps, and jet injectors in the UK is driven by patient preference for convenience, improved glycemic control outcomes, and increasing availability of connected devices with digital health integration.
With over 3.9 million people diagnosed with diabetes in the UK, the growing patient population and rising incidence rates continue to drive demand for innovative insulin delivery solutions.
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Novo Nordisk's insulin delivery portfolio includes reusable pens such as NovoPen 6 and NovoPen Echo Plus, as well as prefilled disposable pens such as FlexPen and FlexTouch. These devices are used by patients requiring insulin injections for diabetes management in home healthcare settings and under healthcare-professional supervision. Smart pens record dose information, while dose-setting mechanisms and prefilled designs simplify insulin administration. | Supports accurate and convenient insulin administration, simplifies dose selection, and improves visibility into previous injections through connected or memory-enabled pens. Prefilled and reusable options accommodate different patient preferences and treatment requirements. |
|
|
embecta provides insulin pen needles, conventional insulin syringes, and safety-engineered injection products. Its portfolio includes Nano pen needles, Ultra-Fine pen needles, AutoShield Duo safety pen needles, and insulin syringes in different needle lengths and barrel capacities. These products support subcutaneous insulin administration by patients at home and healthcare professionals in clinical settings. | Offers flexibility in insulin administration through different needle lengths and syringe capacities. Shorter pen needles support a more comfortable injection experience, while safety-engineered products help reduce the risk of accidental needlestick injuries. |
|
|
Medtronic's MiniMed insulin pump portfolio includes the MiniMed 780G automated insulin delivery system. The system uses continuous glucose monitoring data to adjust insulin delivery and provide automated correction doses. It is designed for eligible people with diabetes requiring insulin and is used in home-based diabetes management with healthcare-professional guidance. | Enables personalized, continuous insulin delivery and automated adjustments based on glucose readings. Integration with glucose sensors can help improve glucose management, reduce the burden of multiple daily injections, and provide patients and care partners with access to diabetes-related information. |
|
|
Sanofi offers insulin delivery devices associated with its insulin portfolio, including the SoloStar prefilled disposable pen and reusable pen options such as AllStar and TouStar in India. These devices are used to administer compatible insulin formulations, including Lantus, Toujeo, and Apidra in applicable presentations and markets. They support routine insulin administration for patients with diabetes in home and clinical settings. | Provides prefilled and reusable delivery options to accommodate different treatment needs. Features such as dose selection, portability, and a prefilled format can simplify insulin administration and support convenient diabetes management. Device and insulin compatibility varies by product and market. |
|
|
Eli Lilly supplies insulin in prefilled delivery devices, including the KwikPen platform used with products such as Humalog, Humulin, and Lyumjev in applicable markets. These pens enable patients requiring insulin therapy to administer prescribed doses through subcutaneous injection, including in home-based settings. Product-specific presentations and indications vary by country. | Provides a convenient, prefilled insulin administration format with dose-selection features that can simplify routine injections. Multiple insulin formulations and pen presentations support different prescribed treatment requirements and help patients manage insulin administration outside healthcare facilities. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | INSULIN PUMPS (Type) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 8.3% from 2025 to 2030 |
| Largest Segment | TYPE 2 DIABETES (Disease Type) |
| Market Size Base Year (Billions) | ~USD 35.37 (2025) |
| Revenue Forecast (Billions) | ~USD 52.7 (2030) |
| Segments Covered | Type, Disease Type, End User |
3 segment dimensions are covered across the global market.
| Segment | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|
| HOME CARE SETTINGS | 800.4 | 860.3 | 927 | 1001.5 | 1084.8 | 1142.7 | 7.4 |
| HOSPITALS & CLINICS | 301.8 | 318.8 | 337.7 | 358.6 | 381.7 | 395.1 | 5.5 |
| OTHER END USERS | 57.4 | 61.2 | 65.5 | 70.1 | 75.3 | 78.7 | 6.5 |
| TOTAL | 1159.6 | 1240.3 | 1330.1 | 1430.2 | 1541.8 | 1616.5 | 6.9 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| KINDRED HEALTHCARE INC. | United States | Private Company | Injectable and infusion-based therapies in long-term acute care hospitals,Oral therapies in inpatient rehabilitation facilities,Contract rehabilitation and ancillary sites using mixed delivery routes, |
| F5 NETWORKS | United States | Public Company | BIG-IP Systems and Packaged Software,NGINX (Plus, One Console, Ingress, WAF),Distributed Cloud Services (WAAP, Multi-cloud Networking, CDN, DNS), |
| DIALOG SEMICONDUCTOR PLC | United Kingdom | Private Company | Custom Mixed Signal (PMICs, battery management, display power, motor control),Advanced Mixed Signal (configurable ICs, AC/DC, LED and SSL drivers),Connectivity & Audio (BLE, Wi-Fi SoCs, audio CODECs), |
Kindred Healthcare Inc. is a United States-based private company founded in 1985 that operates as a major healthcare services provider. With 64,200 employees, the company delivers a range of healthcare services across multiple care settings.
F5 Networks is a publicly traded United States company founded in 1996 with 6,545 employees that specializes in application delivery networking and security solutions.
Dialog Semiconductor PLC is a United Kingdom-based private company founded in 1998 with 2,300 employees that develops semiconductor solutions.
The UK insulin delivery device market is valued at $256.3 million in 2025.
The UK insulin delivery device market is projected to reach $328.4 million by 2030.
The UK insulin delivery device market is expected to grow at a compound annual growth rate (CAGR) of 5.1% from 2025 to 2030.
Key growth drivers in the UK include rising diabetes prevalence, NHS reimbursement policies, patient preference for convenient delivery methods, and innovation in smart and connected insulin devices.
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) provides rigorous oversight that ensures product safety and quality, supporting market confidence and encouraging innovation in insulin delivery technologies.
The study focused on estimating the current market size for the insulin delivery devices sector. Extensive secondary research was conducted to gather information about the insulin delivery devices industry. The next step involved validating the findings, assumptions, and estimates through primary research with industry experts across the value chain. Various approaches were used to estimate the total market size, including top-down and bottom-up methods. Next, market segmentation and data triangulation procedures were used to determine the sizes of the segments and subsegments within the insulin delivery devices market.
The secondary research process relies heavily on secondary sources, including directories and databases such as Bloomberg Businessweek, Factiva, and D&B Hoovers. It also includes white papers, annual reports, investor presentations, company SEC filings, and publications from government sources. Notable examples include the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), the U.S. Census Bureau, the World Health Organization (WHO), the International Trade Administration (ITA), the Global Burden of Disease Study, and the Centers for Medicare and Medicaid Services (CMS). These sources were utilized to gather information for the global insulin delivery devices market study. The process aimed to provide insights into key players, market classification, and segmentation based on industry trends, down to the most detailed level. It also focused on significant developments from both market and technological perspectives. A comprehensive database of key industry leaders was also created using the information obtained through secondary research.
In this report's primary research, we interviewed sources from both the supply and demand sides to gather qualitative and quantitative information. The supply-side primary sources included industry experts such as CEOs, vice presidents, marketing and sales directors, technology and innovation directors, and other key executives from major companies and organizations in the insulin delivery devices market. On the demand side, primary sources included pharmaceutical companies, vaccination centers, hospitals and clinics, pharmacies, and university researchers and academics. This primary research was conducted to validate the market segmentation, identify key players, and gather insights on significant industry trends and market dynamics.

Note 1: C-level primaries include CEOs, CFOs, COOs, and VPs.
Note 2: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
Note 3: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion.
To know about the assumptions considered for the study, download the pdf brochure
For the global market value, annual revenues were calculated based on the revenue mapping of major product manufacturers and OEMs active in the global insulin delivery devices market. All the major product manufacturers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/subsegments was done for the major players. Also, the global insulin delivery devices market was split into various segments and subsegments based on:
The above data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.

After determining the overall size of the global insulin delivery devices market using the methodology above, this market was split into several segments and subsegments. Where applicable, the data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact market value data for the key segments and subsegments. The extrapolated market data were triangulated by analyzing macro indicators and regional trends from both demand- and supply-side participants
Insulin delivery devices are medical devices designed to deliver insulin, a hormone used to manage diabetes, into the body. These devices are primarily used by individuals with diabetes who require insulin therapy to regulate their blood sugar levels. Insulin pens, pumps, pen needles, and syringes are the most widely used delivery devices.
Based on the market data, MarketsandMarkets offers customizations to meet your company’s needs. The following customization options are available for the report:
GEOGRAPHIC ANALYSIS
COMPETITIVE LANDSCAPE ASSESSMENT
Full forecast, segment splits, and company analysis for all Insulin Delivery Device Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report